LENZ Therapeutics is a late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision. Our lead program is an aceclidine based eye drop designed to restore the loss of near vision associated with presbyopia. Presbyopia impacts almost two billion people globally and more than 120 million people in the US. LENZ Therapeutics is headquartered in San Diego, California, and is backed by multiple blue-chip venture capital investors.  

LENZ Therapeutics

IT Specialist

Specialty Sales Representative, Eye Care - Sacramento S, CA

Senior Digital Marketing Manager

VP, Human Resources

LENZ Therapeutics welcomes Kashif Qadeer, O.D. as a Medical Science Liaison in Southern California.

Kashif earned his Doctor of Optometry degree from the Southern California College of Optometry in 2007, following early research experience in ocular medications. He completed a residency in Ocular Disease at the VA Eye Clinic in Las Vegas, then worked in a large ophthalmology practice focusing on LASIK co-management, contact lenses, and clinical research. He later ran a successful two-location private practice in Orange County for over 13 years. Most recently, he returned to the industry side, contributing to clinical research with a major pharmaceutical company.

Join us in welcoming Kashif to the team!

rss_feedRSS News Feed

Lenz Therapeutics: Upcoming PDUFA, Strong Data, Some Risks (NASDAQ:LENZ) - Seeking Alpha

LENZ Therapeutics Reports Third Quarter 2024 Financial Results - The Manila Times

We are hiring! LENZ Therapeutics is searching for a Sr. Regulatory Operations Specialist. 

This position will be responsible for formatting and publishing regulatory submissions, supporting the implementation and maintenance of our Regulatory Information Management and publishing systems, and ensuring compliance with regulatory submissions requirements throughout the product lifecycle. 

Read the full description and click the link to apply: https://lnkd.in/gWSAjYU3 

LENZ Therapeutics Prepares for LNZ100 Launch - TipRanks

LENZ Therapeutics' LNZ100 Hits FDA Milestone, Reports 74% Success in Phase 3 Trial - StockTitan

Graphite Bio Approves Merger, Name Change, and Stock Split - TipRanks

 Shareholder Alert: Ademi LLP investigates whether Graphite Bio, Inc. has obtained a Fair Price in its transaction with LENZ Therapeutics 

 Graphite Bio hands Nasdaq spot to presbyopia biotech Lenz Therapeutics as PhIII readouts loom 

LENZ Therapeutics Debuts With $47 Million Series A Financing - Business Wire

Join LENZ Therapeutics at American Society of Cataract and Refractive Surgery (ASCRS) this week.

Stop by booth #1359 to learn more about the future of presbyopia solutions.

 Lenz Therapeutics' eye drop helps improve vision in late-stage study 

 TD Cowen Upgrades LENZ Therapeutics Inc (LENZ) to Buy 

 Newly Listed Lenz Therapeutics' Vision Loss Experimental Drug Meets Primary Goal In Late-Stage Study 

Corxel and LENZ share positive results from Phase III China trial - The Pharma Letter

Join LENZ Therapeutics at American Optometric Association this week.

Stop by booth #1207 to learn more about the future of presbyopia solutions.

LENZ Therapeutics Stock Is Attractive Before PDUFA (NASDAQ:LENZ) - Seeking Alpha

LENZ Therapeutics is hiring District Sales Managers! 

The District Sales Manager will have an entrepreneurial mindset and get the opportunity to build their own team to achieve high levels of performance. Great opportunity to join a growing company that is focused on developing a new molecule for the pharmacological treatment of presbyopia. 

Apply utilizing the links below. 

Southern California - https://lnkd.in/gdPtiHx3
Pacific West - https://lnkd.in/gNCAKtiv
Southwest - https://lnkd.in/gxRNZdpC
South Central - https://lnkd.in/g_7uryZv
Midwest - https://lnkd.in/gjXv4BS5
Southeast - https://lnkd.in/g_PeFrba
Great Lakes - https://lnkd.in/gN6fz_nD
Mid-South - https://lnkd.in/gUrQQenV
Northeast - https://lnkd.in/gbjJ7S_J
Mid-Atlantic - https://lnkd.in/gVnsCZ6T


LENZ Therapeutics Shares Rise After FDA Accepts Application for Potential Eye Condition Treatment - MarketWatch

LENZ reports positive results from presbyopia treatment trial - Clinical Trials Arena

San Diego’s Lenz Therapeutics snags $83.5M for once-a-day eye drops to replace near-vision glasses - San Diego Union-Tribune

 LENZ Therapeutics Merges With Graphite Bio 

Lenz Therapeutics announces FDA acceptance of NDA for LNZ100 - Yahoo Finance

 LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and ... 

LENZ Therapeutics welcomes Fikret Kajoshaj, O.D. as a Medical Science Liaison in the Southeast. 

Fikret graduated from Nova Southeastern University in Fort Lauderdale, Florida where he obtained his Doctor of Optometry degree in 2013. Fikret furthered his training and completed an ocular disease residency at VA Hudson Valley Health Care System in Westchester County, NY. Fikret practiced and gained extensive and valuable clinical experience working at several different ophthalmology clinics and was a Key Opinion Leader for BioTissue in 2016. 
 
Join us in welcoming Fikret to the team!

LENZ Therapeutics to Host Webcast on First Quarter 2025 Financial Results and Corporate Developments - Nasdaq

 A gene editing biotech's struggles end with reverse merger 

Will LENZ's Presbyopia Eye Drop Disrupt the Vision Care Market? Commercial Strategy Reveal Coming - Stock Titan


                Earnings Release
                HTML
            

We are hiring! LENZ Therapeutics is searching for a Quality Specialist (Product Complaint).

This position will support the development, implementation, and maintenance of Quality Systems necessary for the commercial launch and maintenance of ophthalmic combination products. Position focus is supporting Product Complaint process for commercial product.

Read the full job description and click link below to apply: https://lnkd.in/gcrP2apH 

LENZ Therapeutics, Inc. (LENZ) Is Up 3.37% in One Week: What You Should Know - Yahoo Finance

 LENZ Therapeutics to Participate in Upcoming Investor Conferences 

LENZ - LENZ THERAPEUTICS INC Latest Stock News & Market Updates - Stock Titan

Patent Challenges Threaten Lenz Therapeutics’ Market Strategy and Financial Stability - TipRanks

Piper Sandler raises LENZ Therapeutics stock to Overweight - Investing.com

LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials - Business Wire

Presbyopia Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, NICE Approvals, Mechanism of Action, ROA, IND, NDA Approval and Companies by DelveInsight - The Globe and Mail

Citi ups PT on LENZ Therapeutics on eye-drop approval confidence - TradingView

 LENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024 

Corxel, Lenz's presbyopia therapy hits main goal in late-stage Chinese study - FirstWord Pharma

LENZ Therapeutics Secures FDA Decision Date with $209M War Chest for Presbyopia Drug Launch - Stock Titan

We are hiring! LENZ Therapeutics is searching for a Sr. Quality Specialist.

This position will support the development, implementation, and maintenance of Quality Systems necessary for the commercial launch and maintenance of ophthalmic combination products.

Other responsibilities for this role include date review and verification, support administration of electronic QMS and Regulatory software(s), product complaint handling and management review program. 

If you are ready to join our team, click link below to apply: https://lnkd.in/gmEr7VXj

Companies Like LENZ Therapeutics (NASDAQ:LENZ) Are In A Position To Invest In Growth - Simply Wall St

LENZ partners with Lotus to commercialise presbyopia treatment - Pharmaceutical Technology

LENZ Therapeutics inks deal with Lotus for eye treatment - Investing.com

 LENZ Therapeutics to Host Commercial Day on April 15, 2025 

First-Ever Presbyopia Eye Drop Treatment: LENZ Therapeutics Reveals Latest Progress at BofA Conference - Stock Titan

LENZ Therapeutics gets fresh set of eyes with $47M ...

View All News

LENZ Therapeutics welcomes Apple Decena as our new Senior Accountant. Apple brings a strong background in accounting and has over 8 years of experience in Accounts Receivable and Accounts Payable roles. 

Join us in welcoming Apple to the team!

We're Hopeful That LENZ Therapeutics (NASDAQ:LENZ) Will Use Its Cash Wisely - Yahoo Finance

LENZ Therapeutics, Inc.

LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia - Stock Titan

Mark Schaeffer, OD, FAAO believes presbyopia solutions are active and continuously changing. 
 
"The presbyopia market is dynamic. It reflects our patients’ evolving visual needs and their desire for a solution that provides clear vision on their own terms. Vision is dynamic, too—so shouldn’t we consider a solution that mirrors that?"
 
 www.EyeAmSelective.com
 #presbyopia

LENZ Therapeutics welcomes Marianna Rabinovich as our new Manager of Payroll and Equity Administration. Marianna joins us with nearly 20 years of experience in the HR and Payroll field, with the last 6 years exclusively in the biotech industry, including Poseida Therapeutics, Zentalis Inc. and Bionano. 

Join us in welcoming Marianna to the team!

 Lenz Therapeutics outlines Q4 2025 launch plans for LNZ100 amid FDA review progress 

Walter Whitley, OD looks forward to a new solution for presbyopia that will target the iris sphincter. 

"I’m excited about the future of presbyopia, not only for my patients, but for myself. A solution that selectively targets the iris sphincter to improve near vision is something I’m interested in trying, and it’ll be something my patients welcome too."

LENZ Therapeutics Hosts Commercial Day for LNZ100 - TipRanks

 Lenz Therapeutics' Growth at Risk Amid IP Licensing Battles in Competitive Pharma Landscape - TipRanks.com 

 Insider Trading: RA Capital Buys Stock Worth $15M in LENZ Therapeutics - TipRanks.com 

LENZ Therapeutics Shares Climb After Presbyopia Trial Hits Endpoints - MarketWatch

 LENZ Therapeutics’ $30 Million Private Placement Financing 

Lenz Therapeutics inks $125M licensing deal with Lotus - Axios

 Lenz Therapeutics Completes Merger With Graphite Bio, Inc. 

 LENZ Therapeutics to Present at Upcoming Investor Conferences 

 Lenz Therapeutics management to meet with Piper Sandler 

LENZ Therapeutics Rings the Nasdaq Stock Market Closing Bell - Nasdaq

 LENZ Therapeutics reports positive Phase 3 results for LNZ100 By Investing.com 

LENZ Therapeutics: Time For A Pause (NASDAQ:LENZ) - Seeking Alpha

LENZ Therapeutics: Freedom From Reading Glasses (NASDAQ:LENZ) - Seeking Alpha

Lenz Therapeutics’ Earnings Call Highlights Strong Outlook - MSN

LENZ Therapeutics concludes merger with Graphite Bio - Pharmaceutical Technology

LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress - Business Wire

LENZ Therapeutics inks exclusive commercialization agreement with Lotus Pharmaceutical - MSN

 Lenz Therapeutics, Laboratoires Thea enter license, commercialization agreement 

LENZ Therapeutics Merges With Graphite Bio - San Diego Business Journal

A phenomenal day for LENZ Therapeutics in New York, where we hosted a standout Commercial Day at Nasdaq, showcasing the commercial readiness of LNZ100, our potential best-in-class solution in development for presbyopia.

The event featured powerful first-hand insights from both patients and eye care professionals who participated in our Phase 3 clinical trial — bringing real-world impact to life.

We also shared an exciting preview of our commercial strategy and were thrilled to sit down with special guest Tiffani Thiessen, who brought her own voice to the conversation around presbyopia awareness.

We are energized by the overwhelmingly positive feedback. Thank you to everyone who joined us and to the broader LENZ community for your continued support.

#NASDAQ #Presbyopia #EyeCare #TiffaniThiessen

 Methods for the treatment of presbyopia 

Wilson Sonsini Advises LENZ Therapeutics on Completed Merger with Graphite Bio - Wilson Sonsini

Graphite Erased: LENZ to Merge with Gene Editing Therapy Developer - Genetic Engineering & Biotechnology News

LENZ Therapeutics and Lotus partner for LNZ100 distribution in Asia - World Pharmaceutical Frontiers

Graphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz Therapeutics - Business Wire

Earnings call transcript: LENZ Therapeutics’ Q1 2025 results show innovation drive - Investing.com

Investors & Media

LENZ Therapeutics and JIXING Announce an Exclusive Greater China License Agreement; RTW to Invest in LENZ Therapeutics - Business Wire

We are hiring! LENZ Therapeutics is searching for a Supply Chain Logistics Coordinator. 

This position will support the commercialization of LNZ100 at LENZ. This critical role will focus on coordinating international and domestic shipments and ensuring timely delivery of materials and finished goods through our external manufacturing and warehousing partners. 

Read the full description and click the link to apply: https://lnkd.in/g3pkQfTv 


Transcript : LENZ Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 09 - marketscreener.com

 LENZ Therapeutics and Graphite Bio Announce Merger Agreement 

LENZ Therapeutics Announces $83.5 Million Series B Financing to Advance its Presbyopia Treatments LNZ100 and LNZ101 and Provides Update on Ongoing Phase 3 Studies - Business Wire

LENZ Therapeutics (NASDAQ:LENZ) Trading Up 6.3% - Should You Buy? - MarketBeat

 LENZ Therapeutics, Inc. (LENZ) Files for 13.07M Share Offering by Selling Stockholders 

LENZ Therapeutics and Lotus Pharmaceutical Co., Ltd Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia.

LENZ will receive up to $125 million in upfront, regulatory and commercial milestone payments, as well as tiered, double-digit royalties on future net sales. Lotus will have exclusive development, manufacturing, registration and commercialization rights for LNZ100 for the treatment of presbyopia in the Republic of Korea and certain countries in Southeast Asia, including Thailand, Philippines, Vietnam, Malaysia, Brunei, Indonesia and Singapore.

Read the full press release here: https://lnkd.in/e5QvyN6v

View Press Release

LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Acquired by State Street Corp - MarketBeat

LENZ stock touches 52-week high at $31.05 amid market optimism - Investing.com

 [Video] LENZ Therapeutics on LinkedIn: LENZ Therapeutics welcomes David Choromanski as Vice President of… | 52 ... 

LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference - The Manila Times

Lenz presbyopia drop meets endpoints in near vision improvement in phase 3 trials - Healio

LENZ Therapeutics gets fresh set of eyes with $47M funding to bring eyedrop to market - Fierce Biotech

LENZ Therapeutics

Business:

About: